Controlled inhalation of aerosolised therapeutics

Bibliography

• H B C O' GC Smaldone (Eds), Marcel Dekker, Inc, New York, NY, USA (2002) c2002.
   Google Scholar
• ••An excellent review on all aspects of drugdelivery to the lung.
   Google Scholar
• NEWHOUSE MT: Tennis anyone? The lungs as a new court for systemic therapy. Can. Med. Assoc. J. (1999) 161(10):1287–1288.
   Google Scholar
• •A good review on systemic delivery of drugs via the lung.
   Google Scholar
• HERSHEY AE, KURZMAN ID, FORREST LJ et al.: Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: proof of principle using dogs with spontaneously occurring tumors as a model. Clin. Cancer Res. (1999) 5(9):2653–2659.
   Google Scholar
• BRAND P, BECKMANN H, MAAS ENRIQUEZ M et al.: Peripheral deposition of (11-protease inhibitor using commercial inhalation devices. Eur. Respir. J. (2003) 22:263–267.
   Google Scholar
• BENNETT WD, BROWN JS, ZEMAN KL, HU SC, SCHEUCH G, SOMMERER K: Targeting delivery of aerosols to different lung regions. J. Aerosol Med. (2002) 15:179–188.
   Google Scholar
• •A good review of the factors affecting drug targeting in the lung.
   Google Scholar
• STAHLHOFEN W, RUDOLF G, JAMES AC: Intercomparison of experimental regional aerosol deposition data./ Aerosol Med. (1989) 2(3):285–308.
   Google Scholar
• PAVIA D, THOMSON ML: The fractional deposition of inhaled 2 and 5 micron particles in the alveolar and tracheobronchial regions of the healthy human lung. Ann. Occup. Hygiene (1976) 19:109.
   Google Scholar
• PAVIA D, THOMSON ML, CLARKE SW, SHANNON HS: Effect of lung function and mode of inhalation on penetration of aerosol into the human lung. Thorax (1977) 32(2):194–197.
   Google Scholar
• BROWN JS, ZEMAN KL, BENNETT WD: Regional deposition of coarse particles and ventilation distribution in healthy subjects and patients with cystic fibrosis. J. Aerosol Med. (2001) 14:443–454.
   Google Scholar
• BROWN JS, BENNETT WD: Deposition of coarse particles in cystic fibrosis: model predictions versus experimental results. J. Aerosol Med. (2004) 17(3):239–248.
   Google Scholar
• BROWN JS, BENNETT WD: Optimizing the regional deposition of aerosols in cystic fibrosis. J. Aerosol Med. (2003) 16:204 (Abstract).
   Google Scholar
• HEYDER J, GEBHART J, STAHLHOFEN W, STUCK B: Biological variability of particle deposition in the human respiratory tract during controlled and spontaneous mouth-breathing. Ann. Occup. Hyg. (1982) 26: 137–147.
   Google Scholar
• BRAND P, FRIEMEL I, MEYER T, SCHULZ J, HAUSSINGER K: Total deposition of therapeutic particles during spontaneous and controlled inhalations. J. Pharm. Sci. (2000) 89:724–731.
   Google Scholar
• BENNETT WD, ZEMAN KL, KIM CS: Variability of fine particle deposition in healthy adults: effect of age and gender. Am. J. Resp. Crit. Care Med. (1996) 153(5):1641–1647.
   Google Scholar
• DENYER J, NIKANDER K, SMITH NJ: Adaptive aerosol delivery (AAD®) technology. Expert Opin. DrugDeliv. (2004) 1(1):165–176.
   Google Scholar
• SCHEUCH G, MEYER T, MULLINGER B et al.: Controlled inhalation improves peripheral lung deposition. J. Aerosol Sci. (2001) 14:388.
   Google Scholar
• GRIESE M, RAMAKERS J, KRASSELT A et al.: Improvement of alveolar glutathione and lung function but not oxidative state in cystic fibrosis. Am. J. Respir. Crit. Care Med. (2004) 169:822–828.
   Google Scholar
• KORST RJ, MCELVANEY NG, CHU CS et al.: Gene therapy for the respiratory manifestations of cystic fibrosis. Am. J. Respir. Crit. Care Med. (1995) 151:S75–S87.
   Google Scholar
• STAHLHOFEN W, GEBHART J, RUDOLF G, SCHEUCH G: Measurement of lung clearance with pulses of radioactively labelled particles. J. Aerosol Sci. (1986) 17:333–338.
   Google Scholar
• BENNETT WD, SCHEUCH G, ZEMAN KL et al.: Bronchial airway deposition and retention of particles in inhaled boli: effect of anatomic dead space. Appl. Physiol. (1998) 85:685–694.
   Google Scholar
• ALEXIS NE, HU SC, ZEMAN K, ALTER T, BENNETT WD: Induced sputum derives from the central airways: confirmation using a radiolabeled aerosol bolus delivery technique. Am. J. Resp. Crit. Care Med. (2001) 164:1964–1970.
   Google Scholar
• ANDERSON M, PHILIPSON K, SVARTENGREN M, CAMNER P: Human deposition and clearance of 6 um particles inhaled with an extremely low flow rate. Exp. Lung Res. (1995) 21:187–195.
   Google Scholar
• HAEUSSERMAN S, BRAND P, SCHULTE M et al.: Optimization of lung deposition in patients with cystic fibrosis. Am. J. Resp. Crit. Care Med. (2004) 169(7):A391.
   Google Scholar
• MEYER T, BRAND P, HERPICH C, SCHEUCH G, WEBER N: Controlled inhalation of beta2-sympaticomimetica after bronchial provocation. Pneumologie (2003) 57(11):644–647.
   Google Scholar
• GELLER D, ROSENFELD M, WALTZ DA, WILMOTT RW: Efficiency of Pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system. Chest (2003) 123:28–36.
   Google Scholar
• GELLER D, THIPPHAWONG J, OTULANA B et al.: Bolus inhalation of rhDNase with AERx system in subjects with cystic fibrosis. J. Aerosol Med. (2003) 16:175–182.
   Google Scholar
• BYRNE NM, KEAVEY PM, PERRY JD,GOULD FK, SPENCER DA: Comparison of lung deposition of colomycin using the HaloLite and the Pan i LC Plus nebulisers in patients with cystic fibrosis. Arch. Dis. Child. (2003) 88:715–718.
   Google Scholar